Li Xin, Zhong Hua
a Department of Hematology, Ren Ji Hospital, School of Medicine , Shanghai Jiao Tong University , P.R. China.
Hematology. 2016 Jun;21(5):263-71. doi: 10.1080/10245332.2015.1114766. Epub 2016 Feb 24.
MicroRNAs (miRNAs) are small noncoding RNA molecules that participate in vital cell processes such as proliferation, apoptosis, and differentiation. In recent years, they have been proven to play vital roles in haematological malignancies. In this review we briefly introduce some basic knowledge of microRNAs and summarize their ectopic expression in haematological malignancies, especially in leukaemia. We will also discuss the potential of microRNAs in the diagnosis of leukaemia, in the determination of the clinical prognosis of diverse subtypes, and in targeted therapy.
Despite current adoption of novel biological agents combining traditional chemotherapy regimens, leukaemia remains to have undesirable clinical outcomes due to inaccurate diagnosis, invasiveness of the disease, and patients' intolerance to chemotherapy, thus brand new therapeutic directions are urgently needed. MiRNAs regulate gene expression by means of binding to the 3'-untranslated regions of corresponding mRNAs, leading to the degradation of targeted mRNA or the inhibition of translation. It has been confirmed that they can either function as tumour inhibitors, or may trigger tumourigenesis in certain situations, this specific dual characteristic undoubtedly attract scientists to explore their roles in haematological malignancies. It is of great necessity to summarize the roles of miRNAs in haematological malignancies diagnosis, prognosis evaluation, and clinical treatment.
Future studies may take full advantage of miRNAs detection in diagnosing, in choosing targeted biological therapy, and in avoiding predictable side effect, thus the overall survival rate and cure efficiency of leukaemia should improve.
微小RNA(miRNA)是小型非编码RNA分子,参与细胞增殖、凋亡和分化等重要细胞过程。近年来,已证实它们在血液系统恶性肿瘤中发挥重要作用。在本综述中,我们简要介绍一些微小RNA的基础知识,并总结它们在血液系统恶性肿瘤,尤其是白血病中的异位表达。我们还将讨论微小RNA在白血病诊断、不同亚型临床预后判定及靶向治疗方面的潜力。
尽管目前采用了结合传统化疗方案的新型生物制剂,但由于诊断不准确、疾病侵袭性以及患者对化疗的不耐受性,白血病的临床结局仍不理想,因此迫切需要全新的治疗方向。微小RNA通过与相应信使核糖核酸(mRNA)的3'非翻译区结合来调节基因表达,导致靶向mRNA降解或翻译抑制。已证实它们既可以作为肿瘤抑制因子发挥作用,也可能在某些情况下引发肿瘤发生,这种特殊的双重特性无疑吸引科学家去探索它们在血液系统恶性肿瘤中的作用。总结微小RNA在血液系统恶性肿瘤诊断、预后评估及临床治疗中的作用非常必要。
未来研究可充分利用微小RNA检测进行诊断、选择靶向生物治疗以及避免可预测的副作用,从而提高白血病的总生存率和治愈效率。